Extended Data Fig. 9: A TH2 cell gene-expression signature stratifies patients with cancer for survival probability.
a, A TH2 gene-expression signature was used to perform survival analysis in TCGA Pan Cancer cohort data (n = 10,002) and survival curves were plotted for the signature high group (top 50%; n = 4,996) and low group (bottom 50%; n = 5,006). The corresponding censored patient numbers are included in major time points. Two-tailed log-rank test. b, The TH2 gene signature enrichment score was estimated and plotted for each RNA-sequencing sample of TCGA Pan Cancer patients (n = 10,050). The middle line in the box indicates median and the bound indicates 25% quartile (Q1) and 75% quartile (Q3). The whisker reaches to the max/min point within the 1.5x interquartile range from either Q3 or Q1, respectively. c, The TH2 gene signature was used to perform survival analysis in patients with low-grade glioma (LGG; n = 514) and glioblastoma multiforme (GBM; n = 160), kidney chromophobe (KICH; n = 65) and kidney renal clear cell carcinoma (KIRC; n = 533). The survival curves were plotted for the signature high group (top 50%) and low group (bottom 50%). The corresponding censored patient numbers are included in major time points. Two-tailed log-rank test. d, Representative immunofluorescence images of E-Cadherin (green) and CD31 (red) in KICH (n = 4 patients) and KIRC (n = 8 patients) tumour tissues. Isolated CD31+ staining was counted from 0.2-mm2 regions (n = 9). The stromal regions are marked by dotted lines in KICH samples. Data are shown as mean ± s.e.m. Two-tailed unpaired t-test.
